01.03.2012 | Original Article | Ausgabe 3/2012
Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice
Selwyn J. Hurwitz, Hongzheng Zhang, Sujin Yun, Thil D. Batuwangala, Michael Steward, Steve D. Holmes, Daniel Rycroft, Lin Pan, Mourad Tighiouart, Hyung Ju C. Shin, Lydia Koenig, Yuxiang Wang, Zhuo (Georgia) Chen, Dong M. Shin
01.03.2012 | Original Article | Ausgabe 3/2012
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
Cindy L. O’Bryant, Paul Haluska, Lee Rosen, Ramesh K. Ramanathan, Balaji Venugopal, Stephen Leong, Ramesh Boinpally, Amy Franke, Karsten Witt, Jeffry Evans, Chandra Belani, S. Gail Eckhardt, Suresh Ramalingam
01.03.2012 | Original Article | Ausgabe 3/2012
Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy
Christian H. Brandts, Christiane Schulz, Normann Willich, Björn Steffen, Jendrik Hardes, Georg Gosheger, Winfried Winkelmann, Hubert Serve, Achim Heinecke, Wolfgang E. Berdel, Michael Thomas
01.03.2012 | Original Article | Ausgabe 3/2012
Targeting autophagy enhances BO-1051-induced apoptosis in human malignant glioma cells
Pei-Ming Chu, Li-Hsin Chen, Ming-Teh Chen, Hsin-I Ma, Tsann-Long Su, Pei-Chen Hsieh, Chian-Shiu Chien, Bo-Hua Jiang, Yu-Chih Chen, Yi-Hui Lin, Yang-Hsin Shih, Pang-Hsien Tu, Shih-Hwa Chiou
01.03.2012 | Original Article | Ausgabe 3/2012
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data
Dong Hoe Koo, Seung-Il Park, Yong-Hee Kim, Jong Hoon Kim, Hwoon-Yong Jung, Gin-Hyug Lee, Kee Don Choi, Ho June Song, Ho Young Song, Ji Hoon Shin, Kyung-Ja Cho, Dok-Hyun Yoon, Sung-Bae Kim
01.03.2012 | Original Article | Ausgabe 3/2012
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue
Patrizia Chiusolo, Sabrina Giammarco, Silvia Bellesi, Elisabetta Metafuni, Nicola Piccirillo, Daniela De Ritis, Sara Marietti, Sorà Federica, Luca Laurenti, Luana Fianchi, Stefan Hohaus, Leone Giuseppe, Simona Sica
01.03.2012 | Original Article | Ausgabe 3/2012
Open Access
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
L. Q. M. Chow, N. Blais, D. J. Jonker, S. A. Laurie, S. G. Diab, C. Canil, M. McWilliam, A. Thall, A. Ruiz-Garcia, K. Zhang, L. Tye, R. C. Chao, D. R. Camidge
01.03.2012 | Original Article | Ausgabe 3/2012
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer
Vincent Chung, Elisabeth I. Heath, William R. Schelman, Brendan M. Johnson, Lyndon C. Kirby, Kerlin M. Lynch, Jeffrey D. Botbyl, Thomas A. Lampkin, Kyle D. Holen
01.03.2012 | Original Article | Ausgabe 3/2012
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Samuel R. Denmeade, Susan F. Slovin, Kathy Jelaca-Maxwell, Martha E. Vincent, Howard I. Scher, Michael J. Morris
01.03.2012 | Original Article | Ausgabe 3/2012
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
T. Mazard, M. Ychou, S. Thezenas, S. Poujol, F. Pinguet, A. Thirion, J. P. Bleuse, F. Portales, E. Samalin, E. Assenat
01.03.2012 | Clinical Trial Report | Ausgabe 3/2012
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study
Joseph Chao, Timothy W. Synold, Robert J. Morgan Jr., Charles Kunos, Jeff Longmate, Heinz-Josef Lenz, Dean Lim, Stephen Shibata, Vincent Chung, Ronald G. Stoller, Chandra P. Belani, David R. Gandara, Mark McNamara, Barbara J. Gitlitz, Derick H. Lau, Suresh S. Ramalingam, Angela Davies, Igor Espinoza-Delgado, Edward M. Newman, Yun Yen
